Mostrar el registro sencillo del ítem

Global DNA methylation and hydroxymethylation levels in PBMCs are altered in RRMS patients treated with IFN-β and GA-A preliminary study

dc.creatorReyes-Mata, María Paulinaes_ES
dc.creatorMireles-Ramírez, Mario Albertoes_ES
dc.creatorGriñán-Ferré, Christianes_ES
dc.creatorPallàs, Mercèes_ES
dc.creatorPavón, Lenines_ES
dc.creatorGuerrero-García, José de Jesúses_ES
dc.creatorOrtuño-Sahagún, Danieles_ES
dc.date2023
dc.date.accessioned2025-03-11T17:41:25Z
dc.date.available2025-03-11T17:41:25Z
dc.date.issued2023
dc.identifierJC02NC23es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/8239
dc.identifier.urihttps://doi.org/10.3390/ijms24109074
dc.descriptionMultiple sclerosis (MS) is a chronic disease affecting the central nervous system (CNS) due to an autoimmune attack on axonal myelin sheaths. Epigenetics is an open research topic on MS, which has been investigated in search of biomarkers and treatment targets for this heterogeneous disease. In this study, we quantified global levels of epigenetic marks using an ELISA-like approach in Peripheral Blood Mononuclear Cells (PBMCs) from 52 patients with MS, treated with Interferon beta (IFN-β) and Glatiramer Acetate (GA) or untreated, and 30 healthy controls. We performed media comparisons and correlation analyses of these epigenetic markers with clinical variables in subgroups of patients and controls. We observed that DNA methylation (5-mC) decreased in treated patients compared with untreated and healthy controls. Moreover, 5-mC and hydroxymethylation (5-hmC) correlated with clinical variables. In contrast, histone H3 and H4 acetylation did not correlate with the disease variables considered. Globally quantified epigenetic DNA marks 5-mC and 5-hmC correlate with disease and were altered with treatment. However, to date, no biomarker has been identified that can predict the potential response to therapy before treatment initiation.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation24(10):9074
dc.rightsAcceso Cerradoes_ES
dc.titleGlobal DNA methylation and hydroxymethylation levels in PBMCs are altered in RRMS patients treated with IFN-β and GA-A preliminary studyes_ES
dc.typeArtículoes_ES
dc.contributor.affiliationLaboratorio de Neuroinmunobiología Molecular, Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Mexico
dc.contributor.emailjose.guerrero9683@academicos.udg.mx (J.d.J.G.-G.); daniel.ortuno@academicos.udg.mx (D.O.-S.)
dc.relation.jnabreviadoINT J MOL SCI
dc.relation.journalInternational Journal of Molecular Sciences
dc.identifier.placeSuiza
dc.date.published2023
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1422-0067
dc.identifier.doi10.3390/ijms24109074
dc.subject.kwMultiple sclerosis (MS)
dc.subject.kwEpigenetic
dc.subject.kwDNA methylation
dc.subject.kwDNA hydromethylation
dc.subject.kwHistone acetylation
dc.subject.kwInterferon beta (IFN-β) treatment
dc.subject.kwGlatiramer Acetate (GA) treatment


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem